Comparison of clinical and MRI features of brain metastases between ALK + and ALK ‐ NSCLC
Cancer Medicine · 2024
DOI: 10.1002/cam4.7405 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Xiaolu Ren und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer…. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanxi Province Science Foundation for Youths, Science and Education Cultivation Fund of the National Cancer and Regional Medical Center of Shanxi Provincial Cancer Hospital, Natural Science Foundation of Shanxi Province.
Abstract (Originalsprache)
Background
Non‐small‐cell lung cancer (NSCLC) is the primary cause of brain metastases (BM). This study aimed to investigate differences in clinical and magnetic resonance imaging (MRI) features of BM between anaplastic lymphoma kinase (ALK) gene fusion (ALK+) and ALK wild‐type (ALK‐) NSCLC, and to preliminarily assess the efficacy of radiotherapy for treating BM.
Methods
A retrospective analysis included 101 epidermal growth factor receptor (EGFR)‐ NSCLC patients with BM: 41 with ALK gene fusion and 60 being ALK‐. The brain MRI and clinical features were compared between different ALK status using the multivariate analysis, and a nomogram was constructed to predict ALK gene fusion. Fifty‐six patients who did not undergo cerebral surgery and had complete pre‐ and post‐ treatment data were further divided based on whether they received radiotherapy. Log‐rank test was used to compare the short‐term effect of treatment between the two groups under different genotypes.
Results
ALK+ BM exhibited decreased peritumoral brain edema size, lower peritumoral brain edema index (PBEI), and a more homogeneous contrast enhancement pattern compared to ALK‐ BM. Age (OR = 1.04; 95%CI: 1.02–1.06), time to BM (OR = 1.50; 95% CI: 1.04–2.14), PBEI (OR = 1.26; 95% CI: 0.97–1.62), smoking status (smoking index >400 vs. non‐smoking status: OR = 1.42; 95% CI: 0.99–2.04) and contrast enhancement pattern (OR = 1.89; 95% CI: 1.28–2.78) were associated with ALK gene fusion. A nomogram based on these variables demonstrated acceptable predictive efficiency (AUC = 0.844). In the ALK+ group, patients who received radiotherapy did not show increased disease control rate (DCR) or progression‐free survival (PFS). In contrast, in the ALK‐ group, those who received radiotherapy had improved objective response rate (ORR), DCR, and PFS compared to those who were only treated with systemic therapy.
Conclusions
The clinical and MRI features of BM can indicate the status of ALK in NSCLC. In the ALK‐ group, patients who received radiotherapy showed higher ORR, DCR, and PFS compared to those who did not.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, Ch…
- Department of Radiology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, China.
- Institute of Medical Imaging, Shanxi Medical University, Taiyuan, Shanxi, China.
- Department of Ultrasound, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, Chin…
ORCID-Profile: Xiaolu Ren
Förderung
- Shanxi Province Science Foundation for Youths
- Science and Education Cultivation Fund of the National Cancer and Regional Medical Center of Shanxi Provincial Cancer Hospital
- Natural Science Foundation of Shanxi Province
Zitieren
APA
Ren, X., Zhang, X., Lei, X., Ma, W., Zhang, T., Wang, Y., & Ren, J. (2024). Comparison of clinical and MRI features of brain metastases between ALK + and ALK ‐ NSCLC. Cancer Medicine. https://doi.org/10.1002/cam4.7405
Vancouver
Ren X, Zhang X, Lei X, Ma W, Zhang T, Wang Y, et al. Comparison of clinical and MRI features of brain metastases between ALK + and ALK ‐ NSCLC. Cancer Medicine. 2024. doi:10.1002/cam4.7405
BibTeX
@article{Ren2024,
author = {Ren, Xiaolu and Zhang, Xuting and Lei, Xiaoyan and Ma, Weiqin and Zhang, Ting and Wang, Yuxiang and Ren, Jiwei},
title = {Comparison of clinical and MRI features of brain metastases between ALK + and ALK ‐ NSCLC},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7405}
}
EUVIMED